PORT WASHINGTON, New York, January 14, 2014 /PRNewswire/ --
Equashield (http://www.equashield.com), the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced that it has achieved 60% year-over-year sales growth for the fourth straight year.
Equashield's closed systems reduce the risk of exposure for pharmacy technicians, pharmacists, nurses and other medical professionals who prepare and administer hazardous drugs, such as chemotherapy. In addition, the solution helps to prevent microbial ingress, decreasing the risk of infection in patients receiving these drugs.
"Approximately 20% of hospitals and medical centers are already investing in closed systems to ensure their employees' safety," said Marino Kriheli, Product Manager at Equashield. "With growing awareness of the many risks associated with hazardous drug exposure, this market is rapidly growing. In fact, 55% of new customers Equashield acquired this year did not use closed systems previously. Furthermore, with the recent launch of Equashield II, the company's second generation CSTD, we expect major sales growth to continue in 2014 and beyond."
Equashield is the only preassembled closed syringe that requires no further setup, making it quicker and easier to use than other system on the market. Equashield devices are currently used in the Cleveland Clinic, Mt. Sinai Hospital in New York and hundreds of other medical facilities.
Equashield II covers more routes of exposure to hazardous drugs than alternative systems and is the only system that prevents contamination of syringe plungers by hazardous drugs.
"Contamination on syringe plungers has been clearly identified in recent studies, added
Copyright©2012 PR Newswire.
All rights reserved